Literature DB >> 12574256

Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation.

Spencer W Redding1, William R Kirkpatrick, Stephen Saville, Brent J Coco, William White, Annette Fothergill, Michael Rinaldi, Tony Eng, Thomas F Patterson, Jose Lopez-Ribot.   

Abstract

Candida glabrata has emerged in recent years as a significant cause of systemic fungal infection. We have previously reported on the first three patients receiving radiation for head and neck cancer to develop oropharyngeal candidiasis due to C. glabrata. The goal of this study was to track the development of increased fluconazole resistance in C. glabrata isolates and to evaluate previously described genetic mechanisms associated with this resistance from one of these three patients. The patient was a 52-year-old man with squamous cell carcinoma treated with radiation. At week 7 of his radiation, he developed oropharyngeal candidiasis, which was treated with 200 mg of fluconazole daily for 2 weeks. Serial cultures from this and three subsequent time points yielded C. glabrata. Isolates from these cultures were subjected to antifungal susceptibility testing, DNA karyotyping, and evaluation of the expression of genes previously associated with C. glabrata resistance to fluconazole, CgCDR1, CgCDR2, and CgERG11. Two strains (A and B) of C. glabrata were identified and found to display different patterns of resistance development and gene expression. Strain A developed resistance over a 2-week period and showed no overexpression of these genes. In contrast, strain B first showed resistance 6 weeks after fluconazole therapy was discontinued but showed overexpression of all three genes. In conclusion, development of resistance to fluconazole by C. glabrata is a highly varied process involving multiple molecular mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574256      PMCID: PMC149712          DOI: 10.1128/JCM.41.2.619-622.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

3.  Persistent oral candidosis by non-albicans Candida strains including Candida glabrata in a human immunodeficiency virus-infected patient observed over a period of 6 years.

Authors:  L Hoegl; E Thoma-Greber; M Röcken; H C Korting
Journal:  Mycoses       Date:  1998 Sep-Oct       Impact factor: 4.377

4.  Molecular biological characterization of an azole-resistant Candida glabrata isolate.

Authors:  P Marichal; H Vanden Bossche; F C Odds; G Nobels; D W Warnock; V Timmerman; C Van Broeckhoven; S Fay; P Mose-Larsen
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Electrophoretic karyotyping and triazole susceptibility of Candida glabrata clinical isolates.

Authors:  F Barchiesi; L Falconi Di Francesco; D Arzeni; F Caselli; D Gallo; G Scalise
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-03       Impact factor: 3.267

6.  Natural defenses against Candida colonization breakdown in the oral cavities of the elderly.

Authors:  S R Lockhart; S Joly; K Vargas; J Swails-Wenger; L Enger; D R Soll
Journal:  J Dent Res       Date:  1999-04       Impact factor: 6.116

7.  Comparison of four methods for DNA typing of clinical isolates of Candida glabrata.

Authors:  Luigi Falconi Di Francesco; Francesco Barchiesi; Francesca Caselli; Oscar Cirioni; Giorgio Scalise
Journal:  J Med Microbiol       Date:  1999-10       Impact factor: 2.472

8.  Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors:  J L Lopez-Ribot; R K McAtee; L N Lee; W R Kirkpatrick; T C White; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 9.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Comparison of pulsed-field gel electrophoresis with isoenzyme profiles as a typing system for Candida tropicalis.

Authors:  B N Doebbeling; P F Lehmann; R J Hollis; L C Wu; A F Widmer; A Voss; M A Pfaller
Journal:  Clin Infect Dis       Date:  1993-03       Impact factor: 9.079

View more
  30 in total

1.  Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.

Authors:  Annemarie Borst; Maria T Raimer; David W Warnock; Christine J Morrison; Beth A Arthington-Skaggs
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 2.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  Antifungal resistance of Candida glabrata vaginal isolates and development of a quantitative reverse transcription-PCR-based azole susceptibility assay.

Authors:  Scott E Gygax; John-Paul Vermitsky; Sean G Chadwick; Matthew J Self; Jessica A Zimmerman; Eli Mordechai; Martin E Adelson; Jason P Trama
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

4.  Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.

Authors:  Jon A Olson; Jill P Adler-Moore; P J Smith; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Azole resistance of Candida glabrata in a case of recurrent fungemia.

Authors:  Brunella Posteraro; Mario Tumbarello; Marilena La Sorda; Teresa Spanu; Enrico Maria Trecarichi; Flavia De Bernardis; Giancarlo Scoppettuolo; Maurizio Sanguinetti; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

6.  UPC2A is required for high-level azole antifungal resistance in Candida glabrata.

Authors:  Sarah G Whaley; Kelly E Caudle; John-Paul Vermitsky; Sean G Chadwick; Geoffrey Toner; Katherine S Barker; Scott E Gygax; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

7.  Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.

Authors:  John-Paul Vermitsky; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Monia Maracci; Annette W Fothergill; Isabella Baldassarri; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

10.  Mechanisms of azole resistance in petite mutants of Candida glabrata.

Authors:  Sophie Brun; Thierry Bergès; Pascal Poupard; Carole Vauzelle-Moreau; Gilles Renier; Dominique Chabasse; Jean-Philippe Bouchara
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.